PMH40 - COST-MINIMISATION ANALYSIS OF SECOND GENERATION LONG ACTING INJECTABLES (RISPERIDONE , PALIPERIDONE, AND ARIPIPRAZOLE) FOR SCHIZOPHRENIA IN SPANISH MEDIUM-LONG TERM CARE PSYCHIATRIC UNITS | Publicación